journal article·2022-05

Rational Development of a Polysaccharide–Protein‐Conjugated Nanoparticle Vaccine Against SARS‐CoV‐2 Variants and Streptococcus pneumoniae (Adv. Mater. 21/2022)

Yongqiang Deng, Jing Li, Chunyun Sun, Hang Chi, Dan Luo, Rui Wang, Hongying Qiu, Yanjing Zhang, Mei Wu, Xiao Zhang, Xun Huang, Liangzhi Xie, Chengfeng Qin

Advanced Materials· Volume 34· Issue 21
Publisher page

Abstract

Nanoparticle Vaccines In article number 2200443, Liangzhi Xie, Chengfeng Qin, and co-workers develop a novel bivalent nanoparticle vaccine that confers protection against infection of multiple SARS-CoV-2 variants and Streptococcus pneumoniae. This universal polysaccharide–protein-conjugated vaccine platform provides a powerful tool to fight against cocirculating viral and bacterial pathogens worldwide.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Immunotherapy and Immune Responses · Advanced Drug Delivery Systems · SARS-CoV-2 and COVID-19 Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Virology State Key Laboratory of Pathogen and Biosecurity Beijing Institute of Microbiology and Epidemiology AMMS Beijing 100071 P. R. China

Beijing Protein and Antibody R&D Engineering Center Sinocelltech Ltd. Beijing 100176 P. R. China

Research Unit of Discovery and Tracing of Natural Focus Diseases Chinese Academy of Medical Sciences Beijing 100071 P. R. China

References

Reference metadata was not supplied for this record.